Operator
Hello, and welcome to the Immuneering conference call to discuss the positive 9-month update announced last week from the company’s ongoing Phase IIa trial of atebemetinib and first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Monday, September 29, 2025.
I would now like to turn the call over to Laurence Watts of New Street Investor Relations. Please go ahead.
Laurence Watts
Thank you, operator. Joining us on the call today from Immuneering are Co-Founder and Chief Executive Officer, Ben Zeskind; Chief Scientific Officer, Brett Hall; Chief Medical Officer; Igor Matushansky; Chief Accounting Officer and Treasurer, Mallory Morales and E.B Brakewood, our Chief Business Officer.
During this call, management will make forward-looking statements, including statements related to its Phase IIa trial of atebimetinib as well as the timing of additional data from the study and the company’s development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties.
Factors that could cause these results to be different from those statements include factors the company described in its security filings, including its annual report on Form 10-K and our quarterly report on Form 10-Q. Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.
With that, I will turn the call over to Ben Zeskind, Chief Executive Officer of Immuneering. Ben?
Benjamin Zeskind
Co-Founder, President, CEO & Director
Thank you, Laurence, and good morning, everyone. We are excited
#Immuneering #Corporation #Special #Call